European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
Go back to European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors| Gilead Sciences (NASDAQ: GILD) | Delayed: 145.14 +1.42 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.72 | 52 Week High | $108.63 | |||
| Open | $144.26 | 52 Week Low | $71.39 | |||
| Day High | $146.22 | P/E | 80.19 | |||
| Day Low | $143.71 | EPS | $1.81 | |||
| Volume | 873,954 | |||||
